RT Journal Article
SR Electronic
T1 Serum calcification propensity is associated with HbA1c in type 2 diabetes mellitus
JF BMJ Open Diabetes Research & Care
JO BMJ Open Diab Res Care
FD American Diabetes Association
SP e002016
DO 10.1136/bmjdrc-2020-002016
VO 9
IS 1
A1 Rik Mencke
A1 Amarens van der Vaart
A1 Andreas Pasch
A1 Geert Harms
A1 Femke Waanders
A1 Henk J G Bilo
A1 Harry van Goor
A1 Jan-Luuk Hillebrands
A1 Peter R van Dijk
YR 2021
UL http://drc.bmj.com/content/9/1/e002016.abstract
AB Introduction Serum calcification propensity is emerging as an independent predictor for cardiovascular outcomes in high-risk populations. Calcification propensity can be monitored by the maturation time of calciprotein particles in serum (T50 test). A low T50 value is an independent determinant of cardiovascular morbidity and mortality in various populations. Aim was to investigate the T50 and its relationship to type 2 diabetes mellitus.Research design and methods Using nephelometry, serum T50 was cross-sectionally measured in 932 stable patients with type 2 diabetes mellitus (55% male) with a median age of 66 (62–75) years, diabetes duration of 6.5 (3.0–10.2) years and hemoglobin A1c (HbA1c) of 49 (44–54) mmol/mol.Results Serum T50 was normally distributed with a mean value of 261±66 min. In linear regression, serum T50 was lower in women and current smokers. A lower T50 value was found in patients with a higher HbA1c or higher systolic blood pressure, insulin users and patients with a longer history of diabetes. The association with HbA1c was independent of other determinants in multivariable analysis. There was no association between T50 and previous macrovascular events or the presence of microvascular disease.Conclusions Serum calcification propensity is independently associated with glycemic control, suggesting that a lower HbA1c may be associated with better cardiovascular outcomes. Retrospective analysis could not establish an association between a history of macrovascular events and T50, and prospective studies will have to be performed to address this hypothesis.Trial registration number NCT01570140.